These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 19619339)

  • 21. Expression of hypoxia-inducible carbonic anhydrase-9 relates to angiogenic pathways and independently to poor outcome in non-small cell lung cancer.
    Giatromanolaki A; Koukourakis MI; Sivridis E; Pastorek J; Wykoff CC; Gatter KC; Harris AL
    Cancer Res; 2001 Nov; 61(21):7992-8. PubMed ID: 11691824
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Proangiogenic tumor proteins as potential predictive or prognostic biomarkers for bevacizumab therapy in metastatic colorectal cancer.
    Bruhn MA; Townsend AR; Khoon Lee C; Shivasami A; Price TJ; Wrin J; Arentz G; Tebbutt NC; Hocking C; Cunningham D; Hardingham JE;
    Int J Cancer; 2014 Aug; 135(3):731-41. PubMed ID: 24374727
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hypoxia inducible factor (HIf1alpha and HIF2alpha) and carbonic anhydrase 9 (CA9) expression and response of head-neck cancer to hypofractionated and accelerated radiotherapy.
    Koukourakis MI; Giatromanolaki A; Danielidis V; Sivridis E
    Int J Radiat Biol; 2008 Jan; 84(1):47-52. PubMed ID: 17852557
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hypertension and overall survival in metastatic colorectal cancer patients treated with bevacizumab-containing chemotherapy.
    Österlund P; Soveri LM; Isoniemi H; Poussa T; Alanko T; Bono P
    Br J Cancer; 2011 Feb; 104(4):599-604. PubMed ID: 21304526
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer.
    Jubb AM; Hurwitz HI; Bai W; Holmgren EB; Tobin P; Guerrero AS; Kabbinavar F; Holden SN; Novotny WF; Frantz GD; Hillan KJ; Koeppen H
    J Clin Oncol; 2006 Jan; 24(2):217-27. PubMed ID: 16365183
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antiangiogenic therapy for primary liver cancer: correlation of changes in dynamic contrast-enhanced magnetic resonance imaging with tissue hypoxia markers and clinical response.
    Yopp AC; Schwartz LH; Kemeny N; Gultekin DH; Gönen M; Bamboat Z; Shia J; Haviland D; D'Angelica MI; Fong Y; DeMatteo RP; Allen PJ; Jarnagin WR
    Ann Surg Oncol; 2011 Aug; 18(8):2192-9. PubMed ID: 21286939
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Integration of novel agents in the treatment of colorectal cancer.
    Iqbal S; Lenz HJ
    Cancer Chemother Pharmacol; 2004 Sep; 54 Suppl 1():S32-9. PubMed ID: 15309512
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characteristics of carbonic anhydrase 9 expressing cells in human intestinal crypt base.
    Takahashi H; Suzuki Y; Nishimura J; Haraguchi N; Ohtsuka M; Miyazaki S; Uemura M; Hata T; Takemasa I; Mizushima T; Yamamoto H; Doki Y; Mori M
    Int J Oncol; 2016 Jan; 48(1):115-22. PubMed ID: 26648507
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review.
    Tol J; Punt CJ
    Clin Ther; 2010 Mar; 32(3):437-53. PubMed ID: 20399983
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan.
    Sathornsumetee S; Cao Y; Marcello JE; Herndon JE; McLendon RE; Desjardins A; Friedman HS; Dewhirst MW; Vredenburgh JJ; Rich JN
    J Clin Oncol; 2008 Jan; 26(2):271-8. PubMed ID: 18182667
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CA9 expression as a prognostic factor in renal clear cell carcinoma.
    Soyupak B; Erdoğan S; Ergin M; Seydaoğlu G; Kuzgunbay B; Tansuğ Z
    Urol Int; 2005; 74(1):68-73. PubMed ID: 15711113
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings.
    Kubicka S; Greil R; André T; Bennouna J; Sastre J; Van Cutsem E; von Moos R; Osterlund P; Reyes-Rivera I; Müller T; Makrutzki M; Arnold D;
    Ann Oncol; 2013 Sep; 24(9):2342-9. PubMed ID: 23852309
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study.
    Kozloff M; Yood MU; Berlin J; Flynn PJ; Kabbinavar FF; Purdie DM; Ashby MA; Dong W; Sugrue MM; Grothey A;
    Oncologist; 2009 Sep; 14(9):862-70. PubMed ID: 19726453
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CA9 overexpression is an independent favorable prognostic marker in intrahepatic cholangiocarcinoma.
    Gu M
    Int J Clin Exp Pathol; 2015; 8(1):862-6. PubMed ID: 25755787
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE).
    Grothey A; Sugrue MM; Purdie DM; Dong W; Sargent D; Hedrick E; Kozloff M
    J Clin Oncol; 2008 Nov; 26(33):5326-34. PubMed ID: 18854571
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pimonidazole binding and tumor vascularity predict for treatment outcome in head and neck cancer.
    Kaanders JH; Wijffels KI; Marres HA; Ljungkvist AS; Pop LA; van den Hoogen FJ; de Wilde PC; Bussink J; Raleigh JA; van der Kogel AJ
    Cancer Res; 2002 Dec; 62(23):7066-74. PubMed ID: 12460928
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biologic Response of Colorectal Cancer Xenograft Tumors to Sequential Treatment with Panitumumab and Bevacizumab.
    Taniguchi H; Baba Y; Sagiya Y; Gotou M; Nakamura K; Sawada H; Yamanaka K; Sakakibara Y; Mori I; Hikichi Y; Soeda J; Baba H
    Neoplasia; 2018 Jul; 20(7):668-677. PubMed ID: 29802988
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Exploring racial differences in outcome and treatment for metastatic colorectal cancer: results from a large prospective observational cohort study (BRiTE).
    Polite BN; Sing A; Sargent DJ; Grothey A; Berlin J; Kozloff M; Feng S
    Cancer; 2012 Feb; 118(4):1083-90. PubMed ID: 21800287
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bevacizumab in the treatment of metastatic colorectal cancer (mCRC) in second- and third-line settings.
    Giantonio BJ
    Semin Oncol; 2006 Oct; 33(5 Suppl 10):S15-8. PubMed ID: 17145520
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer.
    Hurwitz HI; Yi J; Ince W; Novotny WF; Rosen O
    Oncologist; 2009 Jan; 14(1):22-8. PubMed ID: 19144677
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.